Cambridge Antibody - Directors Shareholding
August 18 1997 - 11:43AM
UK Regulatory
RNS No 8448u
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
DEALINGS BY DIRECTORS
1) NAME OF COMPANY
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
2) NAME OF DIRECTOR
DR KEVIN STUART JOHNSON
3) Please state whether notification indicates that it is in
respect of holding of the Director named in 2 above
or holding of that person's spouse or children under
the age of 18 or in respect of a non-beneficial interest
DIRECTOR NAMED IN 2 ABOVE
4) Name of the registered holder(s) and, if more than
one holder, the number of shares held by each of
them. (If notified)
N/A
5) Please state whether notification relates to a
person(s) connected with the Director named in 2
above and identify the connected person(s)
N/A
6) Please state the nature of the transaction. For
PEP transactions please indicate whether
general/single co PEP and if discretionary/non
discretionary
APPOINTMENT AS A DIRECTOR ON 11 JULY 1997
7) Number of shares/amount of
stock acquired
N/A
8) ( N/A %)
of issued Class
9) Number of shares/amount
of stock disposed
N/A
10) ( N/A %)
of issued Class
11) Class of security
N/A
12) Price per share
N/A
13) Date of transaction
N/A
14) Date company informed
N/A
15) Total holding following this notification
N/A
16) Total percentage holding of issued class following
this notification
N/A
IF A DIRECTOR HAS BEEN GRANTED OPTIONS BY THE COMPANY PLEASE COMPLETE
THE FOLLOWING BOXES
17) Date of grant
14 FEBRUARY 1992 - 62,500 OPTIONS
4 SEPTEMBER 1996 - 75,000 OPTIONS
18) Period during which or date on which exercisable
14 FEBRUARY 1994 - 8 SEPTEMBER 2002
4 SEPTEMBER 1999 - 3 SEPTEMBER 2006
19) Total amount paid (if any) for grant of the option
#1-00 FOR 14 FEBRUARY 1992 OPTIONS
4 SEPTEMBER 1996 OPTIONS - NIL
20) Description of shares or debentures involved:
class, number.
ORDINARY SHARES 10P
21) Exercise price (if fixed at time of grant) or indication
that price is to be fixed at time of exercise
14 FEB 1992 - #0.12P / 4 SEPT 1996 -#5.00
22) Total number of shares or debentures over which
options held following this notification
137,500
23) Any additional information
N/A
24) Name of contact and telephone number for queries
A N NIXON 01763 263233
25) Name and signature of authorised company official
responsible for making this notification
Date of Notification...18TH AUGUST 1997.............
DEALINGS BY DIRECTORS
1) NAME OF COMPANY
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
2) NAME OF DIRECTOR
DR DAVID ROY GLOVER
3) Please state whether notification indicates that it is in
respect of holding of the Director named in 2 above
or holding of that person's spouse or children under
the age of 18 or in respect of a non-beneficial interest
DIRECTOR NAMED IN 2 ABOVE
4) Name of the registered holder(s) and, if more than
one holder, the number of shares held by each of
them. (If notified)
DR DAVID ROY GLOVER
5) Please state whether notification relates to a
person(s) connected with the Director named in 2
above and identify the connected person(s)
N/A
6) Please state the nature of the transaction. For
PEP transactions please indicate whether
general/single co PEP and if discretionary/non
discretionary
APPOINTMENT AS A DIRECTOR ON 11 JULY 1997
7) Number of shares/amount of
stock acquired
N/A
8) ( N/A %)
of issued Class
9) Number of shares/amount
of stock disposed
N/A
10) ( N/A %)
of issued Class
11) Class of security
ORDINARY
12) Price per share
#5.00
13) Date of transaction
25 MARCH 1997
14) Date company informed
11 JULY 1997
15) Total holding following this notification
6,200
16) Total percentage holding of issued class following
this notification
0.028%
IF A DIRECTOR HAS BEEN GRANTED OPTIONS BY THE COMPANY PLEASE COMPLETE
THE FOLLOWING BOXES
17) Date of grant
28 APRIL 1995 (50,000 OPTIONS)
4 SEPTEMBER 1996 (25,000 OPTIONS)
18) Period during which or date on which exercisable
28 APRIL 1998 - 27 APRIL 2005
4 SEPTEMBER 1999 - 3 SEPTEMBER 2006
19) Total amount paid (if any) for grant of the option
NIL
20) Description of shares or debentures involved:
class, number.
ORDINARY SHARES 10P
21) Exercise price (if fixed at time of grant) or indication
that price is to be fixed at time of exercise
28 APRIL 1995 -#1-28 / 4 SEPT 1996 -#5-00
22) Total number of shares or debentures over which
options held following this notification
75,000
23) Any additional information
N/A
24) Name of contact and telephone number for queries
A N NIXON 01763 263233
25) Name and signature of authorised company official
responsible for making this notification
Date of Notification...18TH AUGUST 1997.............
END
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jul 2023 to Jul 2024
